Inflammatory mediators and the failing heart: past, present, and the foreseeable future.

Recent studies have identified the importance of proinflammatory mediators in the development and progression of heart failure. The growing appreciation of the pathophysiological consequences of sustained expression of proinflammatory mediators in preclinical and clinical heart failure models culminated in a series of multicenter clinical trials that used "targeted" approaches to neutralize tumor necrosis factor in patients with moderate to advanced heart failure. However, these targeted approaches have resulted in worsening heart failure, thereby raising a number of important questions about what role, if any, proinflammatory cytokines play in the pathogenesis of heart failure. This review will summarize the tremendous growth of knowledge that has taken place in this field, with a focus on what we have learned from the negative clinical trials, as well as the potential direction of future research in this area.

[1]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[2]  D. Mann,et al.  Nitric Oxide Provokes Tumor Necrosis Factor-&agr; Expression in Adult Feline Myocardium Through a cGMP-Dependent Pathway , 2000, Circulation.

[3]  G Baumgarten,et al.  Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Harken,et al.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Maury,et al.  Cachectin/tumour necrosis factor-alpha in the circulation of patients with rheumatic disease. , 1989, International journal of tissue reactions.

[6]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[7]  S. Yusuf,et al.  Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry , 1993 .

[8]  D. Stewart,et al.  Effects of VasoCare therapy on the initiation and progression of atherosclerosis. , 2002, Atherosclerosis.

[9]  M. Packer,et al.  Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. , 2001, Journal of cardiac failure.

[10]  Michael G. Shields.  Translator's Introduction , 2001 .

[11]  Anand Kumar,et al.  Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[12]  R. Ferrari,et al.  Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. , 1999, Circulation.

[13]  Simon C Watkins,et al.  Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[15]  D. Mann,et al.  Left Ventricular Remodeling in Transgenic Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor , 2001, Circulation.

[16]  B. Bozkurt,et al.  Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.

[17]  D. Oral,et al.  Effect of Losartan on Circulating TNFα Levels and Left Ventricular Systolic Performance in Patients with Heart Failure , 2001 .

[18]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[19]  D. Mann,et al.  Tumor Necrosis Factor- (cid:97) Confers Resistance to Hypoxic Injury in the Adult Mammalian Cardiac Myocyte , 2022 .

[20]  V. Fadok,et al.  Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. , 1998, The Journal of clinical investigation.

[21]  B. Bozkurt,et al.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.

[22]  R. Voll,et al.  Immunosuppressive effects of apoptotic cells , 1997, Nature.

[23]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[24]  J. Egido,et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.

[25]  S. Nattel,et al.  Characterization of a transient outward K+ current with inward rectification in canine ventricular myocytes. , 1998, American journal of physiology. Cell physiology.

[26]  B. Lucchesi,et al.  Complement activation and inhibition in myocardial ischemia and reperfusion injury. , 1994, Annual review of pharmacology and toxicology.

[27]  M. Kinoshita,et al.  Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[28]  B. Scallon,et al.  Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .

[29]  C. Dinarello,et al.  Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. , 2000, The Journal of infectious diseases.

[30]  B. Bozkurt,et al.  An overview of tumor necrosis factor α and the failing human heart , 1999 .

[31]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[32]  R. Holubkov,et al.  Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy , 2001, Circulation.

[33]  L. Opie,et al.  Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. , 2002, Journal of molecular and cellular cardiology.

[34]  K. Sliwa,et al.  Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy , 1998, The Lancet.

[35]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[36]  P. Poole‐Wilson,et al.  Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. , 1998, QJM : monthly journal of the Association of Physicians.

[37]  K. Weber,et al.  Cardiac interstitium in health and disease: the fibrillar collagen network. , 1989, Journal of the American College of Cardiology.

[38]  S. Weinberger,et al.  Recent trends in protein biochip technology. , 2000, Pharmacogenomics.

[39]  N. Takahashi,et al.  Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. , 1995, The Journal of clinical investigation.

[40]  S. Frøland,et al.  Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. , 1999, Journal of the American College of Cardiology.

[41]  S. Frøland,et al.  Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[42]  S. Nitter‐Hauge,et al.  Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.

[43]  D. Mann,et al.  Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. , 1995, The Journal of clinical investigation.

[44]  J. Kjekshus,et al.  Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). , 2001, American heart journal.

[45]  D. Meldrum.  Tumor necrosis factor in the heart. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[46]  B. Bozkurt,et al.  The Role of Anti-Cytokine Therapy in the Failing Heart , 2001, Heart Failure Reviews.

[47]  S. Swain,et al.  Interleukin 18 , 2001, The Journal of experimental medicine.

[48]  B. Bozkurt,et al.  The role of cytokines in the failing human heart. , 1998, Cardiology clinics.

[49]  M. Runge,et al.  Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-κB (NF-κB) transcription factor , 2004, Molecular and Cellular Biochemistry.

[50]  K. Baker,et al.  The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? , 1999, Circulation research.

[51]  R. Peshock,et al.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.

[52]  M. Entman,et al.  Tumor Necrosis Factor-α Provokes a Hypertrophic Growth Response in Adult Cardiac Myocytes , 1997 .

[53]  D. Zechner,et al.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.

[54]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[55]  OLAND,et al.  TREATMENT OF SEPTIC SHOCK WITH THE TUMOR NECROSIS FACTOR RECEPTOR : Fc FUSION PROTEIN C , 2000 .

[56]  J. Hosenpud,et al.  Interleukin-1-induced myocardial depression in an isolated beating heart preparation. , 1989, The Journal of heart transplantation.

[57]  G. Ramadori,et al.  Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat , 2000, Histochemistry and Cell Biology.

[58]  B. Bozkurt,et al.  Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.

[59]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[60]  D. Mann,et al.  Cytokines as emerging targets in the treatment of heart failure. , 2000, Trends in cardiovascular medicine.

[61]  H. Loetscher,et al.  Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram- negative sepsis , 1994, The Journal of experimental medicine.

[62]  A. Yao,et al.  Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. , 1994, Circulation research.

[63]  G. Schreiner,et al.  Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Banks,et al.  Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. , 1995, Journal of immunology.

[65]  B. Klein,et al.  Cytokine-binding proteins: stimulating antagonists. , 1995, Immunology today.

[66]  R. Peshock,et al.  Cardiac Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-α , 1998 .

[67]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[68]  J. Rouleau,et al.  Effects of Quinapril on Myocardial Function, Ventricular Remodeling and Cardiac Cytokine Expression in Congestive Heart Failure in the Rat , 2004, Cardiovascular Drugs and Therapy.

[69]  C. Szabó,et al.  Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. , 1998, American journal of physiology. Heart and circulatory physiology.

[70]  F. Pagani,et al.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. , 1992, The Journal of clinical investigation.

[71]  G. Freeman,et al.  beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. , 2000, Circulation.

[72]  J. Balligand,et al.  Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. , 1993, The Journal of clinical investigation.

[73]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[74]  F. Graham,et al.  Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. , 1998, The American journal of pathology.

[75]  D. Mann,et al.  Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[76]  Ronald M Peshock,et al.  Magnetic Resonance Imaging and Invasive Evaluation of Development of Heart Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-α , 1999 .

[77]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[78]  C. Natanson,et al.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock , 1989, The Journal of experimental medicine.

[79]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[80]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[81]  G. Dorn,et al.  Sphingosine Mediates the Immediate Negative Inotropic Effects of Tumor Necrosis Factor-α in the Adult Mammalian Cardiac Myocyte* , 1997, The Journal of Biological Chemistry.

[82]  S. Fichtlscherer,et al.  Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients With Advanced Heart Failure , 2001, Circulation.